{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:27:53Z","timestamp":1783607273780,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014351","name":"CinnaGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111436","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T11:34:15Z","timestamp":1703504055000},"page":"111436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Comparative immunogenicity and safety of SpikoGen\u00ae, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial"],"prefix":"10.1016","volume":"127","author":[{"given":"Payam","family":"Tabarsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Mamishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Shahpari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Newsha","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Roshanzamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soudabeh","family":"Oveisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-338X","authenticated-orcid":false,"given":"Saghar","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.intimp.2023.111436_b0005","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1001\/jama.2022.18931","article-title":"Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021","volume":"328","author":"Global Burden of Disease Long","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2023.111436_b0010","doi-asserted-by":"crossref","unstructured":"COVID-19 Vaccines in Children and Adolescents. Pediatrics, 2022. 149(1).","DOI":"10.1542\/peds.2021-054332"},{"issue":"7","key":"10.1016\/j.intimp.2023.111436_b0015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00431-021-03993-5","article-title":"Multisystem inflammatory syndrome in children related to COVID-19: a systematic review","volume":"180","author":"Hoste","year":"2021","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.intimp.2023.111436_b0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"Npj Vaccines"},{"issue":"40","key":"10.1016\/j.intimp.2023.111436_b0025","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2023.111436_b0030","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.intimp.2023.111436_b0035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2023.111436_b0040","article-title":"An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.111436_b0045","article-title":"An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.intimp.2023.111436_b0050","article-title":"An advax-adjuvanted inactivated cell-culture derived japanese encephalitis vaccine induces broadly neutralising anti-flavivirus antibodies, robust cellular immunity and provides single dose protection","volume":"9","author":"Komiya","year":"2021","journal-title":"Vaccines (basel)"},{"issue":"29","key":"10.1016\/j.intimp.2023.111436_b0055","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.vaccine.2020.05.009","article-title":"Adjuvant selection impacts the correlates of vaccine protection against Ebola infection","volume":"38","author":"Stronsky","year":"2020","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.intimp.2023.111436_b0060","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen\u00ae vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.intimp.2023.111436_b0065","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1016\/j.vaccine.2023.10.018","article-title":"Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.intimp.2023.111436_b0070","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1016\/j.vaccine.2023.06.063","article-title":"An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.111436_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.08.053","article-title":"Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice","author":"Sakala","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.111436_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Evaluating the efficacy and safety of SpikoGen\u00ae, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.intimp.2023.111436_b0085","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen\u00ae, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","volume":"28","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.intimp.2023.111436_b0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen\u00ae, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2023.111436_b0095","doi-asserted-by":"crossref","DOI":"10.1111\/imm.13661","article-title":"Ability of SpikoGen\u00ae, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants","author":"Honda-Okubo","year":"2023","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2023.111436_b0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2023.111436_b0105","unstructured":"FDA Briefing Document: Licensure and Emergency Use Authorization of Vaccines to Prevent COVID-19 for Use in Pediatric Populations. 2021."},{"issue":"12","key":"10.1016\/j.intimp.2023.111436_b0110","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/21645515.2018.1502517","article-title":"A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)","volume":"14","author":"Popmihajlov","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.intimp.2023.111436_b0115","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/INF.0000000000000893","article-title":"Pediatric vaccine adjuvants: Components of the modern vaccinologist's toolbox","volume":"34","author":"Dowling","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.intimp.2023.111436_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMsr2105280","article-title":"SARS-CoV-2 variants and vaccines","volume":"385","author":"Krause","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.intimp.2023.111436_b0125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta)","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"Variant. N Engl J Med"},{"issue":"6578","key":"10.1016\/j.intimp.2023.111436_b0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.abm0620","article-title":"SARS-CoV-2 vaccine protection and deaths among US veterans during 2021","volume":"375","author":"Cohn","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.intimp.2023.111436_b0135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","article-title":"Towards a population-based threshold of protection for COVID-19 vaccines","volume":"40","author":"Goldblatt","year":"2022","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.intimp.2023.111436_b0140","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1016\/j.vaccine.2021.10.075","article-title":"Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2023.111436_b0145","first-page":"2287118","article-title":"The characterization of CD8+ T-cell responses in COVID-19","author":"Yang","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"10.1016\/j.intimp.2023.111436_b0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.intimp.2023.111436_b0155","article-title":"Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022","author":"Hall","year":"2023","journal-title":"J Infect"},{"issue":"8","key":"10.1016\/j.intimp.2023.111436_b0160","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157963","article-title":"Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults","volume":"7","author":"Karron","year":"2022","journal-title":"JCI Insight"},{"issue":"21","key":"10.1016\/j.intimp.2023.111436_b0165","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.intimp.2023.111436_b0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.7774\/cevr.2021.10.3.282","article-title":"Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study","volume":"10","author":"Kang","year":"2021","journal-title":"Clin Exp Vaccine Res"},{"issue":"12","key":"10.1016\/j.intimp.2023.111436_b0175","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jamacardio.2021.3471","article-title":"Association of myocarditis With BNT162b2 messenger RNA COVID-19 vaccine in a case series of children","volume":"6","author":"Dionne","year":"2021","journal-title":"JAMA Cardiol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923017630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923017630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:14:49Z","timestamp":1761588889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923017630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":35,"alternative-id":["S1567576923017630"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111436","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative immunogenicity and safety of SpikoGen\u00ae, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111436"}}